Chromium has been sold as a blood sugar mineral for more than 25 years, usually as chromium picolinate in doses of 200 to 1,000 micrograms (mcg). The idea rests on a real body of research: dozens of trials and more than a dozen meta-analyses, studies that pool the results of many trials. But the best-known positive trial was not reproduced when it was repeated in Western countries, the better-run trials mostly found no effect, and experts now disagree about whether chromium is even an essential nutrient. The American Diabetes Association (ADA) names chromium specifically when it says mineral supplements are not recommended for blood sugar.

This guide covers what the trials found for fasting glucose and HbA1c, why better-run trials tend to find less, what the FDA's chromium "health claim" really says, whether the form on the label matters, what is known about safety and drug interactions, and what to check before you buy. For the wider picture, see our blood sugar supplements guide.

The short version

  • The pooled effect is small and shaky. Meta-analyses of trials in type 2 diabetes report average drops in fasting glucose and HbA1c (a measure of average blood sugar over about 3 months, reported as a percentage; a fall from 8.0 to 7.5 percent is a drop of 0.5 points), but the results vary enormously, and a 2007 analysis of 41 studies found larger effects more often in the poorer-quality studies.
  • The famous trial was not reproduced. A 1997 trial in China found a large HbA1c drop at 1,000 mcg a day. Larger, double-blind trials in the Netherlands and the US, including two at the same dose, did not find a clear benefit; one small US trial did.
  • No clear benefit without diabetes. Trials in people with prediabetes, metabolic syndrome or normal blood sugar found no improvement in glucose or insulin sensitivity; one 2023 pooled analysis found only a fasting glucose drop.
  • The ADA says no. Its 2026 Standards of Care say supplements of minerals "such as magnesium or chromium" are not recommended for blood sugar benefits.
  • The FDA claim is not an endorsement. The only claim the FDA allows says the link between chromium picolinate and insulin resistance is "highly uncertain," based on one small study.
  • Safety looks acceptable at usual doses, with rare case reports of kidney, liver and muscle injury at high doses. If you take insulin, other diabetes medicines or levothyroxine, talk with your doctor first.

Chromium for blood sugar at a glance

QuestionWhat the evidence shows
Essential nutrient?Disputed: the US set intake targets in 2001; Europe's food safety agency found no evidence it is essential (2014)
Adult intake target (US)35 mcg a day for men and 25 mcg for women up to age 50 (30 and 20 mcg after 50)
Typical supplement dose200 to 1,000 mcg, or about 6 to 40 times those targets
Type 2 diabetesSmall average drops in pooled trials, larger in poorer studies; better-run Western trials mostly found no effect
Prediabetes or normal blood sugarNo clear benefit in trials
American Diabetes AssociationNot recommended for blood sugar benefits (2026)
FDAAllows one qualified claim that calls the evidence "highly uncertain"
Safety at usual dosesGenerally well tolerated in trials; rare case reports at high doses; no US upper limit set

Intake targets are the Adequate Intakes from the US Food and Nutrition Board, as listed by the NIH Office of Dietary Supplements.

Is chromium even an essential nutrient?

In 2001, the US Food and Nutrition Board treated chromium as essential, based on its apparent effects on insulin, and set Adequate Intakes (an intake level assumed to be enough, used when the data are too thin for a true requirement): 35 mcg a day for men and 25 mcg for women aged 19 to 50, and 30 and 20 mcg from age 51. The daily value on supplement labels is 35 mcg. According to the ODS, the board has not reviewed chromium since.

Opinion has moved since then. In 2014, the European Food Safety Authority (EFSA) concluded that an essential function for chromium had not been substantiated, found no evidence of benefit from chromium intake in healthy people, and decided that setting any intake value, even an Adequate Intake, was not appropriate. The NIH Office of Dietary Supplements (ODS) now notes that recent research suggests chromium is not an essential mineral, because a lack of it does not produce problems that chromium then fixes, and that there is no validated test for chromium status and no clinically defined deficiency.

The whole case for chromium deficiency in people rests on three case reports from 1977 to 1986 of patients fed only by vein (total parenteral nutrition) for months or years, whose high blood sugar improved when chromium was added to the feeding solution. The ODS says scientists have concluded these reports do not show the patients were actually chromium deficient. Most people in the US take in roughly the Adequate Intake from food, and deficiency has not been reported in healthy people.

Why this matters for you: "chromium helps if you are deficient" is a claim you cannot act on, because there is no accepted way to tell whether you are. The doses in supplements are far above what food supplies, so if chromium affects blood sugar at all, it is acting more like a drug than like a nutrient you are missing.

How it might work. How chromium could affect insulin is not settled. Scientists have proposed that a small chromium-binding molecule boosts the activity of the insulin receptor, and others favor different pathways, but the evidence is mostly from rodents and lab studies, often at doses far higher relative to body weight than people take. A leading chromium researcher at the University of Alabama, an inventor on several chromium supplement patents, concluded in 2024 that chromium can no longer be considered an essential trace element and that its effects in rodents are drug-like.

Does chromium lower blood sugar and A1C? What the trials found

The trial that started it. In a 1997 trial in China, 180 adults with type 2 diabetes took a placebo, 200 mcg or 1,000 mcg of chromium picolinate a day for 4 months on top of their usual treatment. At the end, HbA1c was 8.5 percent on placebo, 7.5 percent at 200 mcg and 6.6 percent at 1,000 mcg. Fasting glucose was about 159 mg/dL on placebo versus 128 mg/dL at the high dose. (Blood sugar in the US is measured in milligrams per deciliter, mg/dL; a fasting level under 100 mg/dL is considered normal.) The study was led by a US Department of Agriculture scientist; chromium picolinate was patented by the USDA and licensed to a supplement company. A 2002 meta-analysis noted that, of the three trials it found that reported HbA1c, this was the only one to show a significant drop, and that the combined data from the other, much smaller diabetes trials (38 people in all) showed no effect on glucose or insulin.

Trials that tried to repeat it. Most did not reproduce the result:

  • In a 6-month Dutch trial in people with type 2 diabetes on insulin, HbA1c fell by the same 0.4 points or so on placebo and on 500 or 1,000 mcg of chromium picolinate. A second Dutch trial, using 400 mcg of chromium yeast for 6 months in people on diabetes tablets, also found no difference from placebo.
  • A US trial at the Pennington Biomedical Research Center gave 1,000 mcg of chromium picolinate or a placebo to 137 people with type 2 diabetes for 24 weeks and found no significant effect on insulin sensitivity, fasting glucose or HbA1c compared with placebo. About half the people on chromium were classed as "responders"; they tended to start with worse insulin sensitivity and higher blood sugar. But in an earlier 6-month trial by the same group, 30 percent of placebo takers were also classed as responders, against 63 percent on chromium, so some apparent responses are not caused by chromium.
  • One small US trial was positive: in Vermont, 29 people taking the diabetes drug glipizide saw HbA1c fall 1.16 points on 1,000 mcg compared with 0.4 points on placebo over 6 months.
  • A Brazilian trial of chromium nicotinate at 50 or 200 mcg for 90 days found no improvement in blood sugar, insulin sensitivity or cholesterol.

Positive trials elsewhere. Most trials reporting benefits were small and came from China, India, Iran, Brazil, Iraq and other countries, and several were single-blind (the researchers knew who got chromium) or compared people only with their own starting values. A 4-month Brazilian trial of 71 people with poorly controlled diabetes, for example, reported HbA1c falling 1.9 points on 600 mcg versus 1.0 point on placebo, but it was single-blind. The largest analysis, from 2023, pooled 64 mostly short trials and found chromium lowered HbA1c in both Western and non-Western participants, and fasting glucose only in Western ones, so the mixed results are not simply about geography. The authors still called for large, high-quality, long-term trials.

What the meta-analyses say. The pooled results depend heavily on which trials are included:

  • A 2007 analysis of 41 studies, almost half of poor quality, found HbA1c 0.6 points lower and fasting glucose about 18 mg/dL lower in type 2 diabetes, no benefit in people without diabetes, and larger effects more often in the poor-quality studies.
  • A 2014 analysis of 25 trials, three of them combination products, found HbA1c 0.55 points lower and fasting glucose about 21 mg/dL lower.
  • A 2013 analysis of 7 trials found lower fasting glucose but no significant change in HbA1c, and a 2015 analysis that grouped trials by chromium form found that none of the forms it could test lowered HbA1c.
  • A 2020 analysis of 28 studies found HbA1c about 0.7 points lower and fasting glucose 19 mg/dL lower on average, but the plausible range for glucose (the 95 percent confidence interval) ran from about 36 mg/dL down to under 2 mg/dL, and the trials disagreed with each other about as much as trials can (a heterogeneity score of 99.8 percent).
  • A 2022 analysis limited to 10 trials found a lower HbA1c but no significant change in fasting glucose.

A 2016 review by NIH Office of Dietary Supplements scientists took a different approach: instead of averaging, it asked whether chromium helped people reach treatment goals. Across 20 trials in type 2 diabetes, fasting glucose reached the treatment goal in 5 of 20, and HbA1c reached it in 3 of the 14 trials that measured it. The authors concluded that chromium has limited effectiveness and there is little reason to recommend it for blood sugar control in people with type 2 diabetes.

How strong is the evidence?

Weak, for several reasons:

  • Quality tracks the result: the better-designed, double-blind Western trials mostly found no effect, and the 2007 analysis found larger effects more often in poorer studies.
  • Huge disagreement between trials: heterogeneity in several meta-analyses was close to the maximum, which means a single average says little about what any one person can expect.
  • Short trials: most lasted 2 to 6 months, and in PubMed searches through November 2026 we found no chromium blood sugar trial lasting a year or longer.
  • No health outcomes: in PubMed and ClinicalTrials.gov searches through November 2026, we found no trial that tested whether chromium affects the risk of developing diabetes, diabetes complications, heart disease or death.
  • Small trials: in PubMed and ClinicalTrials.gov searches through November 2026, no completed trial of chromium alone in diabetes enrolled more than the 180 people of the 1997 trial.
  • Industry links: several trials used products donated or funded by chromium makers, and one follow-up analysis was written by a maker's employees, though some independent trials also used donated product.

Consistent with this, the ADA's 2026 Standards of Care say supplements of micronutrients "such as magnesium or chromium" are "not recommended for glycemic benefits," meaning blood sugar benefits, and that the evidence does not support routine use of chromium to improve blood sugar in type 1 or type 2 diabetes. The ODS says chromium lowered fasting glucose and HbA1c slightly in people with diabetes, but that the clinical significance of these findings is unclear. Chromium is not a substitute for diabetes medicines, and nothing here suggests it can treat or prevent diabetes.

Prediabetes, insulin resistance and the FDA claim

If chromium works mainly on insulin resistance (when the body responds less well to insulin), people with prediabetes would seem the obvious group to benefit. The trials say otherwise:

  • A Yale trial gave 500 or 1,000 mcg of chromium picolinate to 59 adults with prediabetes or metabolic syndrome over 6 months and found no change in glucose, insulin or insulin resistance. The authors concluded chromium is unlikely to lower diabetes risk.
  • A University of Pennsylvania trial of 1,000 mcg for 16 weeks in 63 adults with obesity and metabolic syndrome found no significant improvement in insulin sensitivity.
  • A double-blind trial in people with impaired glucose tolerance (blood sugar above normal after a sugar drink, but below the diabetes range) found chromium did not improve glucose tolerance, insulin sensitivity or cholesterol.
  • A UCSF trial of 1,000 mcg for 16 weeks in 31 adults with normal blood sugar found no improvement in insulin sensitivity, and higher blood chromium levels were linked with worse insulin sensitivity; the authors urged caution.

Reviews from 2002 and 2007 also found no effect on glucose or insulin in people without diabetes.

About the FDA "health claim." Chromium picolinate labels sometimes carry a claim about insulin resistance. A supplement company petitioned the FDA for eight claims about chromium picolinate. In 2005, the FDA found no credible evidence for six of them (three about heart disease, plus high blood sugar, eye disease and kidney disease) and allowed only this wording about insulin resistance and type 2 diabetes:

"One small study suggests that chromium picolinate may reduce the risk of insulin resistance, and therefore possibly may reduce the risk of type 2 diabetes. FDA concludes, however, that the existence of such a relationship between chromium picolinate and either insulin resistance or type 2 diabetes is highly uncertain."

The FDA ranked the evidence at the lowest level it accepts for a qualified claim and noted the one small study had not been replicated. This is not FDA approval. It is the FDA agreeing not to object to a heavily qualified statement, and it is about risk in people without diabetes, not treatment.

Picolinate, polynicotinate, GTF: does the form matter?

All forms of chromium are poorly absorbed. The ODS puts absorption at about 0.4 to 2.5 percent, with roughly 1.2 percent for chromium picolinate and 0.4 percent for chromium chloride, and says these figures are similar to absorption from food. Studies that compared forms by measuring chromium in urine disagree: one found picolinate gave higher levels than two niacin-bound (nicotinate) products and chloride, another found chromium histidinate higher than picolinate, and a study that tracked tagged chromium in people and rats found picolinate was not retained any better than another form tested. In PubMed searches through November 2026, we found no human trial of chromium histidinate for blood sugar.

More important, better absorption has not translated into better results. A 2015 meta-analysis grouped trials by form and found that none of the three forms it could test for HbA1c (picolinate, chromium yeast and brewer's yeast) lowered it; only brewer's yeast lowered fasting glucose, in four small trials. Other analyses favored picolinate or chloride. No form has a consistent advantage.

  • Chromium picolinate is the most studied form and was used in the 1997 Chinese trial and most US trials. See our chromium picolinate page.
  • Chromium polynicotinate ("niacin-bound chromium") is chromium bound to niacin. The niacin is a tiny amount, about 1 milligram per 200 mcg of chromium on the labels we checked, roughly a thousandth of the doses of niacin used to lower cholesterol. See our chromium polynicotinate page.
  • "GTF" chromium. Glucose tolerance factor was a proposed natural chromium complex studied from the 1950s on, but no chemically defined GTF compound has ever been identified. Today, labels use "GTF" for picolinate, polynicotinate, yeast or chelates alike, so the word tells you nothing about the form. See our GTF chromium page.

The amount on the label is elemental chromium, the chromium itself, not the weight of the whole compound. Doses are far above the daily value: 200 mcg is 571 percent of the 35 mcg daily value and 1,000 mcg is 2,857 percent. Older labels may show smaller percentages, such as 167 percent for 200 mcg, because the daily value used to be 120 mcg.

Weight loss, cravings, PCOS and cholesterol

  • Weight loss: a 2013 Cochrane review, from an independent network known for strict methods, found about 1.1 kilograms (about 2.4 pounds) more weight loss than placebo, rated the evidence low quality and called the effect of debatable clinical relevance. Another 2013 analysis found about 0.5 kilograms (about 1 pound), a 2019 analysis of 21 trials found about 0.75 kilograms (about 1.7 pounds) and called the clinical relevance uncertain, and a 2024 analysis of 14 trials in type 2 diabetes found no significant change in weight. A controlled-diet USDA trial in 83 women found no effect on weight or body fat. In 1996 the Federal Trade Commission (FTC) alleged that the company marketing chromium picolinate made weight-loss, fat-loss and diabetes claims without a reasonable basis, and the company settled. See our guide to whether fat burners work.
  • Cravings and appetite: one 8-week trial in 42 overweight women with carbohydrate cravings found less food intake, less hunger and fewer fat cravings with chromium picolinate, but no significant difference in weight. A trial in atypical depression found no difference on its main measures; a smaller group with strong carbohydrate cravings did better in an after-the-fact analysis, which needs confirming.
  • PCOS: meta-analyses in polycystic ovary syndrome (PCOS, a hormonal condition often linked to insulin resistance) disagree. One found a lower body mass index, another found lower insulin resistance in two small trials but no change in fasting insulin, and a third concluded chromium may not have significant benefits, with total and free testosterone higher on chromium. See our PCOS supplements guide and inositol for PCOS.
  • Cholesterol: a 2021 analysis found small drops in triglycerides and total cholesterol that the authors said may not be clinically important, and a 2023 review of eight meta-analyses found no significant effect on any blood lipid.

Is chromium safe?

Supplements contain trivalent chromium, written Cr(III). It is a different substance from hexavalent chromium, Cr(VI), the industrial pollutant known to cause cancer. In trials, chromium at 200 to 1,000 mcg a day for up to about 6 months generally caused no more side effects than placebo, although many trials did not report side effects carefully. But in PubMed searches through November 2026 we found no studies of long-term safety in people, and a 2014 review reached the same conclusion.

  • No US upper limit: the Food and Nutrition Board found no adverse effects linked to high chromium intakes from food or supplements, so it did not set a tolerable upper intake level. The ODS says caution may still be warranted and that people with kidney or liver disease might be more susceptible. Europe set a tolerable daily intake for Cr(III) of 0.3 milligrams per kilogram of body weight, far above supplement doses. See our guide to upper limits and megadosing.
  • The DNA damage question: 1990s lab studies found chromium picolinate damaged chromosomes in hamster cells, while other chromium forms did not. A 2-year US National Toxicology Program study fed rats and mice very large amounts of chromium picolinate and found no evidence of cancer in female rats or in mice, and only "equivocal" evidence in male rats (a rise in one benign gland tumor at the middle dose only). The animal results were largely reassuring, but the long-term human question has not been studied.
  • Case reports: isolated reports describe kidney failure, liver injury, anemia, low platelets, muscle breakdown (rhabdomyolysis) and skin reactions after chromium supplements. In one case, a 33-year-old woman taking 1,200 to 2,400 mcg a day of chromium picolinate for 4 to 5 months for weight loss developed kidney failure needing dialysis, liver injury and anemia, and recovered after stopping. In another, a bodybuilder developed muscle breakdown after taking 1,200 mcg over 48 hours. Some reports involved products with several ingredients.
  • Pregnancy and breastfeeding: the intake targets are 30 mcg a day in pregnancy and 45 mcg while breastfeeding for adults. In PubMed searches through November 2026, we found no safety data on chromium supplements in pregnancy or breastfeeding, so get chromium from food and a prenatal vitamin unless your provider advises otherwise.

Chromium side effects and drug interactions

  • Insulin, metformin and other diabetes medicines: the ODS says chromium could add to the effect of these medicines and might increase the risk of low blood sugar. In PubMed searches through November 2026 we found only two published case reports of low blood sugar blamed on chromium, and the trials we reviewed did not report excess low blood sugar. If you take diabetes medicines, talk with your doctor first, check your glucose more often when you start, and do not change your medicines on your own.
  • Levothyroxine (thyroid hormone): in a study of 7 healthy volunteers, taking chromium picolinate together with levothyroxine reduced how much of the thyroid hormone was absorbed. The study authors advised taking them several hours apart. See our guide to supplement and drug interactions.
  • Antacids, vitamin C and aspirin: antacids reduce chromium absorption, and vitamin C and aspirin increase it, according to the ODS. These are effects on absorption, not proven clinical problems.
  • Kidney or liver disease: skip chromium supplements unless your doctor recommends them.
  • Common side effects: a 2013 review of weight trials listed watery stools, vertigo, headaches and hives.

How to choose a chromium supplement

  • Ask whether you need it at all. For blood sugar, the ADA does not recommend it, and there is no test that shows you are low. Diet, physical activity, weight loss when needed and prescribed medicines have far stronger evidence. If you are comparing other options, see our guides to magnesium for insulin resistance, cinnamon for blood sugar and berberine supplements.
  • Food first. Meats, whole grains, vegetables such as green beans and lettuce, fruits such as apples and bananas, grape and orange juice, brewer's yeast and nuts supply chromium, though amounts vary widely with soil and processing. A multivitamin usually adds 35 to 120 mcg.
  • Keep the dose modest. Most trials used 200 to 1,000 mcg a day. Higher doses have no better evidence, and the serious case reports mostly involved high doses, such as 1,200 to 2,400 mcg a day in the kidney failure case.
  • Ignore "GTF" and absorption claims. "GTF" does not identify a form, and no form has shown better blood sugar results. Claims that one form is "hundreds of percent more bioavailable" are marketing, not trial results.
  • Read combination labels. Chromium often appears in blood sugar blends with cinnamon, berberine, biotin or herbs, which makes it hard to know what you are taking or which ingredient causes a side effect. One 90-day trial of 600 mcg chromium picolinate plus 2 mg biotin, registered by the company that sells the combination, found HbA1c fell about 0.5 points on the combination, significantly more than on placebo; that result applies to the combination, not to chromium alone. The ADA's 2026 recommendation names cinnamon as well as chromium as not recommended for blood sugar. See how to read a supplement facts label.
  • Look for third-party testing. A seal from a testing program such as USP or NSF shows the product was independently checked for what is on the label.
  • Tell your clinician, and set a time limit. Most trials lasted 2 to 6 months, and HbA1c reflects about 3 months of blood sugar, so a practical approach is to check HbA1c about 3 months after starting and stop if it has not improved. Judge any effect by your own glucose readings and HbA1c, not by how you feel, and do not use chromium instead of prescribed treatment.

Frequently asked questions

Does chromium lower blood sugar?

Perhaps slightly in some people with type 2 diabetes, but the evidence is weak. Pooled trials report small average drops in fasting glucose and HbA1c, mostly driven by small, lower-quality trials, while most better-run trials in the Netherlands and the US found no effect. Trials in people without diabetes mostly found no benefit. The American Diabetes Association does not recommend chromium for blood sugar.

Does chromium picolinate lower A1C?

Results are mixed. Some meta-analyses found HbA1c about 0.5 to 0.7 points lower, others found no significant change, and a 2015 analysis by chromium form found that none of the forms it could test lowered HbA1c. The best-known large drop came from a 1997 trial in China that later trials did not reproduce.

Why does the American Diabetes Association not recommend chromium?

Its 2026 Standards of Care say supplements of micronutrients such as magnesium or chromium are not recommended for blood sugar benefits, because the evidence does not support routine use. The trials are small, short and inconsistent, and none has shown benefits for diabetes complications or long-term health.

Is chromium picolinate FDA approved for diabetes?

No. The FDA allows one qualified claim for chromium picolinate, which says one small study suggests it may reduce the risk of insulin resistance, and therefore possibly type 2 diabetes, but that the relationship is highly uncertain. The FDA found no credible evidence for six other requested claims, about high blood sugar, heart disease, eye disease and kidney disease.

How much chromium should I take a day?

No dose has been shown to work reliably. The US Adequate Intake is 35 mcg a day for men and 25 mcg for women aged 19 to 50, which most people get from food. Trials used mostly 200 to 1,000 mcg a day. If you try a supplement, keep to that range, and talk with your doctor if you take diabetes medicines.

How long does chromium take to work?

No study has defined a trial period. Most trials lasted 2 to 6 months, and HbA1c reflects about 3 months of blood sugar, so if you try chromium with your doctor's agreement, a practical check is your HbA1c about 3 months after starting. If it has not improved, there is little reason to continue.

Is 1,000 mcg of chromium too much?

No US upper limit has been set, and trials at 1,000 mcg a day for up to about 6 months generally reported no more side effects than placebo, though few trials tracked harms carefully. But 1,000 mcg is about 29 times the men's Adequate Intake, higher doses have no better evidence, and rare reports of kidney, liver or muscle injury have involved doses from about 600 mcg a day upward or multi-ingredient products. Long-term safety in people has not been studied.

Can chromium help with prediabetes or insulin resistance?

The trials say no. Studies at Yale, the University of Pennsylvania, UCSF and elsewhere found no improvement in glucose, insulin or insulin sensitivity in people with prediabetes, metabolic syndrome or normal blood sugar. In PubMed searches through November 2026, we found no trial that tested whether chromium lowers the risk of developing type 2 diabetes.

Is chromium an essential nutrient?

That is now disputed. The US set Adequate Intakes in 2001, but in 2014 the European Food Safety Authority found that an essential role had not been substantiated and set no intake value. The NIH Office of Dietary Supplements says there is no validated test for chromium status and no defined deficiency state in healthy people.

Which form of chromium is best?

No form has shown better blood sugar results. All forms are poorly absorbed, roughly 0.4 to 2.5 percent, and studies comparing them disagree. Chromium picolinate is the most studied. GTF on a label does not identify a form, and claims that one form is far more bioavailable are not backed by trials.

Does chromium help you lose weight or stop sugar cravings?

Only a little, if at all. A Cochrane review found about 1.1 kilograms (2.4 pounds) more weight loss than placebo and rated the evidence low quality. One small trial in women with carbohydrate cravings found less hunger and fewer fat cravings, but weight did not change significantly. In 1996 the FTC charged the company marketing chromium picolinate with making weight-loss claims without a reasonable basis.

Does chromium help with PCOS?

The evidence is mixed. Meta-analyses in polycystic ovary syndrome found lower body mass index or lower insulin resistance in some analyses, but no change in fasting insulin in others, and one concluded chromium may not have significant benefits.

Can I take chromium with metformin or insulin?

Talk with your doctor first. The NIH Office of Dietary Supplements says chromium could add to the effect of diabetes medicines and might increase the risk of low blood sugar, although only two case reports of this were found. If you start it, check your blood sugar more often and do not change your medicines on your own.

Does chromium interact with levothyroxine?

It may. In a small study of 7 healthy volunteers, taking chromium picolinate together with levothyroxine reduced how much of the thyroid hormone was absorbed. The study authors advised taking them several hours apart; tell your doctor if you start or stop chromium.

Is chromium picolinate safe for the kidneys and liver?

In trials it was generally well tolerated, but isolated case reports describe kidney failure and liver injury, the best documented at 1,200 to 2,400 mcg a day for months. People with kidney or liver disease may be more susceptible and should not take chromium supplements unless their doctor recommends them.

Is chromium the same as the toxic chromium in pollution?

No. Supplements and food contain trivalent chromium, Cr(III). The toxic industrial form is hexavalent chromium, Cr(VI), which is a known carcinogen. They are different substances.

What foods are high in chromium?

Meats, whole grains, vegetables such as green beans and lettuce, fruits such as apples and bananas, grape and orange juice, brewer's yeast and nuts all supply chromium. Amounts vary widely with soil and processing, and most people in the US get roughly the Adequate Intake from food.

The bottom line

Chromium may lower blood sugar slightly in some people with type 2 diabetes, but the positive results come mostly from small, lower-quality trials, the famous 1997 trial was not reproduced in Western countries, and trials in people without diabetes mostly found no benefit. Whether chromium is even an essential nutrient is now disputed. The American Diabetes Association does not recommend it for blood sugar, and the FDA's only allowed claim calls the evidence "highly uncertain."

At usual doses chromium appears reasonably safe for most adults, but it is not a diabetes treatment. If you want to try it, keep the dose modest, keep your medicines as prescribed, check your blood sugar if you take diabetes medicines, and talk with your doctor if you have kidney or liver disease or take levothyroxine.

VS
Reviewed for accuracy by
Vladimir Salamakha

B.S. in Chemistry, University of South Florida · a formulation scientist with 15 years developing compliant, evidence-based products across nutritional supplements and personal care. More about the author →

A quick note This article is general information about research on chromium, not medical advice, and nothing here suggests that chromium or any supplement can diagnose, treat, cure, or prevent any disease. If you have diabetes or prediabetes, take insulin, other blood sugar medicines, levothyroxine or other prescription drugs, have kidney or liver disease, or are pregnant or breastfeeding, talk with your doctor before taking chromium supplements.
Sources
American Diabetes Association Professional Practice Committee for Diabetes. 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes 2026. Diabetes Care, 2026. PMID 41358898. · NIH Office of Dietary Supplements. Chromium: Fact Sheet for Health Professionals, updated June 2, 2022; and Chromium: Fact Sheet for Consumers, accessed November 2026. · US Food and Drug Administration. Qualified Health Claims: Letter of Enforcement Discretion, Chromium Picolinate and Insulin Resistance (Docket No. 2004Q-0144), August 25, 2005. · European Food Safety Authority, Panel on Dietetic Products, Nutrition and Allergies. Scientific Opinion on Dietary Reference Values for chromium. EFSA Journal 2014;12(10):3845. · European Food Safety Authority, Panel on Contaminants in the Food Chain. Scientific Opinion on the risks to public health related to the presence of chromium in food and drinking water. EFSA Journal 2014;12(3):3595. · Federal Trade Commission. Nutrition 21, et al.; Analysis to Aid Public Comment (proposed consent agreement). Federal Register 61(222):58562, November 15, 1996. · National Toxicology Program. Toxicology and carcinogenesis studies of chromium picolinate monohydrate in F344/N rats and B6C3F1 mice (feed studies). NTP Technical Report 556, 2010. PMID 20725156. · ClinicalTrials.gov searches for chromium trials in diabetes, prediabetes, insulin resistance, metabolic syndrome, obesity and PCOS, accessed November 2026; NIH Dietary Supplement Label Database, chromium labels, accessed November 2026. · Anderson RA et al. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes, 1997. PMID 9356027 (4-month trial in 180 people with type 2 diabetes in China). · Althuis MD et al. Glucose and insulin responses to dietary chromium supplements: a meta-analysis. Am J Clin Nutr, 2002. PMID 12081828 (meta-analysis of 15 trials, 2002). · Kleefstra N et al. Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: a randomized, double-blind, placebo-controlled trial. Diabetes Care, 2006. PMID 16505499 (6-month Dutch trial in insulin-treated type 2 diabetes: no effect). · Kleefstra N et al. Chromium treatment has no effect in patients with type 2 diabetes in a Western population: a randomized, double-blind, placebo-controlled trial. Diabetes Care, 2007. PMID 17303791 (6-month Dutch trial of chromium yeast: no effect). · Cefalu WT et al. Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus. Metabolism, 2010. PMID 20022616 (24-week US trial in 137 people with type 2 diabetes). · Wang ZQ et al. Phenotype of subjects with type 2 diabetes mellitus may determine clinical response to chromium supplementation. Metabolism, 2007. PMID 17998017 (earlier trial by the same group: responders on placebo too). · Martin J et al. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care, 2006. PMID 16873787 (6-month trial in 29 people taking glipizide). · Albarracin CA et al. Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. Diabetes Metab Res Rev, 2008. PMID 17506119 (90-day trial of chromium picolinate plus biotin). · Guimarães MM et al. Chromium nicotinate has no effect on insulin sensitivity, glycemic control, and lipid profile in subjects with type 2 diabetes. J Am Coll Nutr, 2013. PMID 24024769 (90-day Brazilian trial of chromium nicotinate: no effect). · Paiva AN et al. Beneficial effects of oral chromium picolinate supplementation on glycemic control in patients with type 2 diabetes: A randomized clinical study. J Trace Elem Med Biol, 2015. PMID 26302914 (4-month single-blind trial in 71 people with type 2 diabetes). · Wan S et al. Chromium Supplementation to Reduce Cardiometabolic Risk Factors: A Novel Dose-Response Meta-Analysis of Randomized Clinical Trials. JACC Adv, 2023. PMID 38938494 (analysis of 64 trials, 2023). · Balk EM et al. Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. Diabetes Care, 2007. PMID 17519436 (systematic review of 41 studies, 2007). · Suksomboon N et al. Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes. J Clin Pharm Ther, 2014. PMID 24635480 (meta-analysis of 25 trials, 2014). · Abdollahi M et al. Effect of chromium on glucose and lipid profiles in patients with type 2 diabetes; a meta-analysis review of randomized trials. J Pharm Pharm Sci, 2013. PMID 23683609 (meta-analysis of 7 trials, 2013). · Yin RV et al. Effect of chromium supplementation on glycated hemoglobin and fasting plasma glucose in patients with diabetes mellitus. Nutr J, 2015. PMID 25971249 (meta-analysis by chromium form, 2015). · Asbaghi O et al. Effects of chromium supplementation on glycemic control in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res, 2020. PMID 32730903 (meta-analysis of 28 studies, 2020). · Zhao F et al. Effect of Chromium Supplementation on Blood Glucose and Lipid Levels in Patients with Type 2 Diabetes Mellitus: a Systematic Review and Meta-analysis. Biol Trace Elem Res, 2022. PMID 33783683 (meta-analysis of 10 trials, 2022). · Costello RB et al. Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness. Nutr Rev, 2016. PMID 27261273 (review of 20 trials against treatment goals, NIH authors). · Landman GW et al. Chromium does not belong in the diabetes treatment arsenal: Current evidence and future perspectives. World J Diabetes, 2014. PMID 24748929 (review: no evidence of long-term safety studies). · Ali A et al. Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus. Endocr Pract, 2011. PMID 20634174 (Yale trial in prediabetes and metabolic syndrome). · Iqbal N et al. Chromium picolinate does not improve key features of metabolic syndrome in obese nondiabetic adults. Metab Syndr Relat Disord, 2009. PMID 19422140 (16-week trial in metabolic syndrome). · Gunton JE et al. Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile: a randomized, placebo-controlled, double-blind trial of supplementation in subjects with impaired glucose tolerance. Diabetes Care, 2005. PMID 15735214 (trial in impaired glucose tolerance). · Masharani U et al. Chromium supplementation in non-obese non-diabetic subjects is associated with a decline in insulin sensitivity. BMC Endocr Disord, 2012. PMID 23194380 (16-week trial in people with normal blood sugar). · Trumbo PR et al. Chromium picolinate intake and risk of type 2 diabetes: an evidence-based review by the United States Food and Drug Administration. Nutr Rev, 2006. PMID 16958312 (FDA evidence-based review of the qualified claim). · Anderson RA et al. Stability and absorption of chromium and absorption of chromium histidinate complexes by humans. Biol Trace Elem Res, 2004. PMID 15564651 (absorption of chromium histidinate vs picolinate). · DiSilvestro RA et al. Comparison of acute absorption of commercially available chromium supplements. J Trace Elem Med Biol, 2007. PMID 17499152 (absorption of four commercial chromium supplements). · Laschinsky N et al. Bioavailability of chromium(III)-supplements in rats and humans. Biometals, 2012. PMID 22814636 (radiolabel absorption study in rats and humans). · Vincent JB et al. Chromium. Adv Nutr, 2018. PMID 30032219 (review: no defined glucose tolerance factor). · Vincent JB. Is chromium(III) pharmacologically relevant? An update focused on studies with diabetic rodent models. J Trace Elem Med Biol, 2024. PMID 38653006 (review arguing chromium is not essential). · Jeejeebhoy KN et al. Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium supplementation, in a patient receiving long-term total parenteral nutrition. Am J Clin Nutr, 1977. PMID 192066 (case report, intravenous feeding). · Freund H et al. Chromium deficiency during total parenteral nutrition. JAMA, 1979. PMID 104057 (case report, intravenous feeding). · Brown RO et al. Chromium deficiency after long-term total parenteral nutrition. Dig Dis Sci, 1986. PMID 3086063 (case report, intravenous feeding). · Tian H et al. Chromium picolinate supplementation for overweight or obese adults. Cochrane Database Syst Rev, 2013. PMID 24293292 (Cochrane review of chromium picolinate for weight). · Onakpoya I et al. Chromium supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials. Obes Rev, 2013. PMID 23495911 (meta-analysis of weight trials, 2013). · Tsang C et al. A meta-analysis of the effect of chromium supplementation on anthropometric indices of subjects with overweight or obesity. Clin Obes, 2019. PMID 31115179 (meta-analysis of 21 weight trials, 2019). · Vajdi M et al. Effects of chromium supplementation on body composition in patients with type 2 diabetes: A dose-response systematic review and meta-analysis of randomized controlled trials. J Trace Elem Med Biol, 2024. PMID 37952433 (body composition meta-analysis in type 2 diabetes, 2024). · Lukaski HC et al. Chromium picolinate supplementation in women: effects on body weight, composition, and iron status. Nutrition, 2007. PMID 17291720 (12-week controlled-diet trial in 83 women). · Anton SD et al. Effects of chromium picolinate on food intake and satiety. Diabetes Technol Ther, 2008. PMID 18715218 (8-week trial in 42 women with carbohydrate cravings). · Docherty JP et al. A double-blind, placebo-controlled, exploratory trial of chromium picolinate in atypical depression: effect on carbohydrate craving. J Psychiatr Pract, 2005. PMID 16184071 (8-week trial in atypical depression). · Fazelian S et al. Chromium supplementation and polycystic ovary syndrome: A systematic review and meta-analysis. J Trace Elem Med Biol, 2017. PMID 28595797 (PCOS meta-analysis, 2017). · Heshmati J et al. The Effects of Supplementation with Chromium on Insulin Resistance Indices in Women with Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Horm Metab Res, 2018. PMID 29523006 (PCOS meta-analysis, 2018). · Tang XL et al. Chromium supplementation in women with polycystic ovary syndrome: Systematic review and meta-analysis. J Obstet Gynaecol Res, 2018. PMID 28929602 (PCOS meta-analysis, 2018). · Asbaghi O et al. Effects of chromium supplementation on lipid profile in patients with type 2 diabetes: A systematic review and dose-response meta-analysis of randomized controlled trials. J Trace Elem Med Biol, 2021. PMID 33813266 (lipid meta-analysis, 2021). · Vajdi M et al. Effects of Chromium Supplementation on Lipid Profile: an Umbrella of Systematic Review and Meta-analysis. Biol Trace Elem Res, 2023. PMID 36376714 (umbrella review of lipid meta-analyses, 2023). · Stearns DM et al. Chromium(III) picolinate produces chromosome damage in Chinese hamster ovary cells. FASEB J, 1995. PMID 8529845 (chromosome damage in hamster cells). · Cerulli J et al. Chromium picolinate toxicity. Ann Pharmacother, 1998. PMID 9562138 (case report: kidney failure, liver injury and anemia). · Martin WR et al. Suspected chromium picolinate-induced rhabdomyolysis. Pharmacotherapy, 1998. PMID 9692662 (case report: rhabdomyolysis). · Bunner SP et al. Chromium-induced hypoglycemia. Psychosomatics, 1998. PMID 9664781 (case report: low blood sugar). · Bharmal SV et al. Hypoglycaemia: possible mediation by chromium salt medication. Hormones (Athens), 2010. PMID 20687403 (case report: low blood sugar). · John-Kalarickal J et al. New medications which decrease levothyroxine absorption. Thyroid, 2007. PMID 17725434 (levothyroxine absorption study in 7 volunteers).